Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib for Recurrent Craniopharyngioma
NCT06970145Phase 2Recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Apr 2025
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib in craniopharyngioma, sponsored by Nanfang Hospital, Southern Medical University. Started Apr 2025; status: recruiting.
02
Drugs
anlotinib
03
Conditions
craniopharyngioma
Beyond the preview
Go deeper on NCT06970145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06970145.